VJOncology
LightNews LightNews
banner
vjoncology.bsky.social
VJOncology
@vjoncology.bsky.social
330 followers 170 following 160 posts
The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise 🩺 🎥 🗞️
#BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm
Posts Replies Media Videos
Pinned
vjoncology.bsky.social
VJOncology @vjoncology.bsky.social · Nov 18
Welcome!👋

We are a global, open access, expert-led video journal bringing healthcare professionals trustworthy, cutting-edge news in #Oncology🔦

🏥Disease areas www.vjoncology.com/subjects/#all

🎧VJOncology Podcast www.vjoncology.com/podcasts/

📩VJOncology Newsletter www.vjoncology.com/newsletter/
vjoncology.bsky.social
Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate
EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology
Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...
buff.ly
November 11, 2025 at 3:54 PM
vjoncology.bsky.social
At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.

🎥 Watch: buff.ly/vLWxnoe

#BCSM #CTSM #TrialUpdate #Oncology
EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer - VJOncology
Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...
buff.ly
November 10, 2025 at 3:54 PM
vjoncology.bsky.social
🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.

Watch here ➡️ buff.ly/E4FLjXD

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25
Metastatic breast cancer updates at ESMO 2025 - VJOncology
Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...
buff.ly
November 9, 2025 at 9:01 AM
vjoncology.bsky.social
Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease

🎥 buff.ly/dLhijGf

#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25
RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology
Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...
buff.ly
November 8, 2025 at 9:05 AM
vjoncology.bsky.social
Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.

💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC

🎥 buff.ly/r3AwOkw

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social
DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer - VJOncology
Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...
buff.ly
November 7, 2025 at 9:01 AM
vjoncology.bsky.social
Nima Nabavizadeh, MD, presents #PATHFINDERII data on multi-cancer early detection.

🧬 cfDNA test detects cancer signal & origin
📈 High specificity & PPV
⚕️ Boosted early-stage cancer detection

🎥 buff.ly/LDR0AgW

#CancerScreening #Oncology #ESMO25
PATHFINDER II: assessing the efficacy and safety of a MCAD test - VJOncology
Nima Nabavizadeh, MD, Oregon Health & Science University, Portland, OR, discusses the PATHFINDER II study (NCT05155605), evaluating a multi-cancer early...
buff.ly
November 6, 2025 at 9:01 AM
vjoncology.bsky.social
Neal Shore, MD, FACS shares final OS data from EMBARK in high-risk BCR prostate cancer.

💊 Enzalutamide + leuprolide ↓ risk of death vs leuprolide alone
📈 Improved progression & skeletal outcomes
✅ Confirms enzalutamide-based therapy as SoC
🎥 buff.ly/LBEmrOa

#ProstateCancer #ESMO25 #UroOnc #UroSoMe
EMBARK: final OS results of enzalutamide in hrBCR prostate cancer - VJOncology
Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses final overall survival results from the Phase III...
buff.ly
November 5, 2025 at 2:06 PM
vjoncology.bsky.social
Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors

🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure

🎥 buff.ly/ozWqgdG

#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25
FORAGER-1: dose optimization of LY3866288 in FGFR3-altered tumors - VJOncology
Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...
buff.ly
November 2, 2025 at 9:01 AM
vjoncology.bsky.social
Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.

💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk

#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer - VJOncology
Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...
buff.ly
November 1, 2025 at 9:01 AM
vjoncology.bsky.social
Andreas Dietz, MD, PhD, discusses the ADRISK Phase IIb trial in adjuvant HNSCC.

💉 Pembrolizumab + chemoradiation
➡️ No sig. EFS/OS gain, but favorable trends
⚖️ Safety consistent; supports further study
🎥 buff.ly/NlJqVv0

#HNSCC #Immunotherapy #Oncology #ESMO25
ADRISK: pembrolizumab plus adjuvant chemoradiation in HNSCC - VJOncology
Andreas Dietz, MD, PhD, University Hospital of Leipzig, Leipzig, Germany, discusses the Phase IIb ADRISK trial (NCT03480672), which evaluated pembrolizumab...
buff.ly
October 30, 2025 at 7:00 PM
vjoncology.bsky.social
At #ESMO25, Enrique Grande, MD, presents results from the Phase II DISCUS trial in aUC.

💊 3 vs 6 chemo cycles before avelumab maintenance
📈 Similar OS & PFS
💪 Better QoL & fewer toxicities with 3 cycles

🎥 buff.ly/UjqkfNT

@myesmo.bsky.social #BladderCancer #ImmunoOnc #GUcancer #Oncology
DISCUS: comparing 3 vs 6 chemotherapy cycles before avelumab in aUC - VJOncology
Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the Phase II DISCUS trial (NCT06892860), which evaluated whether...
buff.ly
October 29, 2025 at 9:03 AM
vjoncology.bsky.social
Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25

🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT

🎥 Watch: buff.ly/dIMvnoC

@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe
COSMIC-313: transcriptomic predictors of metastatic sites in RCC - VJOncology
Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, discusses a post-hoc transcriptomic analysis from...
ow.ly
October 28, 2025 at 7:30 PM
vjoncology.bsky.social
Alexander Wyatt, DPhil, shares IMvigor011 results of ctDNA-guided adjuvant atezolizumab in high-risk #BladderCancer:

🧬 Atezolizumab improved DFS & OS in ctDNA+ pts
🚫 ctDNA– pts had low recurrence risk
✅ Safety consistent with known profile

🎥 Watch: buff.ly/g35zqx2

@myesmo.bsky.social #ESMO25
IMvigor011: ctDNA-guided adjuvant atezolizumab in MIBC - VJOncology
Alexander Wyatt, DPhil, University of British Columbia, Vancouver, Canada, discusses the Phase III IMvigor011 trial (NCT04660344) of circulating tumor (ctDNA)-guided...
buff.ly
October 27, 2025 at 6:05 PM
vjoncology.bsky.social
At #ESMO25, Shigehira Saji shares new MonarchE data on Ki-67 as a biomarker in HR+/HER2– high-risk #BreastCancer:

📊 High Ki-67 = ↑ recurrence risk
💊 Abemaciclib + ET effective across all Ki-67 subgroups
✅ Broad benefit, regardless of Ki-67 change

🎥 Watch: buff.ly/F1mziDY

#BCSM #CTSM #TrialUpdate
MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer - VJOncology
Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the MonarchE trial (NCT03155997) evaluating the prognostic and predictive value...
ow.ly
October 24, 2025 at 8:02 AM
vjoncology.bsky.social
At #ESMO25, Scott Tagawa, MD, MS, FACP, discusses the Phase III PSMAddition trial in PSMA-positive mHSPC:

💥 Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI improved rPFS
📈 OS trend & manageable safety
✅ No major QoL impact

🎥 Watch: buff.ly/vSBfVPS

@myesmo.bsky.social #PCSM #UroOnc #UroSoMe #RadOnc #CTSM
PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC - VJOncology
Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Phase III PSMAddition trial (NCT04720157), which...
buff.ly
October 23, 2025 at 8:03 AM
vjoncology.bsky.social
At #ESMO25, Clara Steiner, MD, presents 5-year results of CheckMate 274 in MIUC

💊 Adjuvant nivolumab vs placebo after surgery
📈 Sustained DFS, OS & disease-specific survival benefit
🧫 ctDNA-positive pts saw enhanced benefit
✅ No new safety concerns

🎥 Watch: buff.ly/ou4EvLv

#UroOnc #UroSoMe #Blcsm
CheckMate 274: 5-year results of adjuvant nivolumab in MIUC - VJOncology
Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, gives an overview of updated 5-year...
buff.ly
October 22, 2025 at 2:54 PM
vjoncology.bsky.social
At #ESMO25, Stephanie Graff, MD, addresses key questions in #BreastCancer care.

💊 Updates on CDK4/6 inhibitors
💪 Managing endocrine therapy toxicities
🌍 Global survivorship & trial access insights

🎥 Watch the full session: buff.ly/LdOXB18

#BCSM #Oncology
Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025 - VJOncology
Stephanie Graff, MD, Brown University Health Cancer Institute, Providence, RI, joins us for an “Ask the Expert” session at ESMO...
buff.ly
October 21, 2025 at 8:02 AM
vjoncology.bsky.social
At #ESMO25, Emmanuel Seront discusses the RENALUT trial of ¹⁷⁷Lu-PSMA-617 in metastatic ccRCC

💥 PSMA-targeted radioligand therapy after TKI + ICI progression
🎯 Evaluating response, PFS, OS, & safety
🧠 Imaging-guided treatment w/ added cycles for responders

🎥 buff.ly/sswLUyk

#kcms #UroOnc #UroSoME
RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology
Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...
buff.ly
October 20, 2025 at 2:54 PM
vjoncology.bsky.social
🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses sequencing IO and radiotherapy in nasopharyngeal carcinoma:

➡️ buff.ly/K24ba3d ⬅️

#ASCO25 #ImmunOnc #hncSM
Sequencing IO and radiotherapy in nasopharyngeal carcinoma - VJOncology
Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on the potential benefits of integrating PD-1 immunotherapy (IO)...
buff.ly
October 20, 2025 at 10:04 AM
vjoncology.bsky.social
🎥Cecile Riviere-Cazaux, PhD, highlights the emerging role cfDNA as novel biomarkers in neuro-oncology, noting their ability to detect molecularly defined biomarkers and monitor treatment response:

➡️ buff.ly/xCKCsRY

#BTSM #Oncology
The future of CSF liquid biopsies in precision medicine for brain tumors - VJOncology
Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, highlights the emerging role cell-free DNA (cfDNA) as novel biomarkers in neuro-oncology, highlighting...
buff.ly
October 17, 2025 at 8:03 AM
vjoncology.bsky.social
🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses current immunotherapy approaches in nasopharyngeal carcinoma:

➡️ buff.ly/egOS3ia

#ASCO25 #ImmunOnc #hncSM
The future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 - VJOncology
Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses current immunotherapy approaches in nasopharyngeal carcinoma. There is a...
buff.ly
October 14, 2025 at 8:02 AM
vjoncology.bsky.social
🎥Christina Fotopoulou, MD, PhD, of @imperialcollegeldn.bsky.social highlights accessibility as a key barrier to optimal surgical care in advanced #OvarianCancer:

Watch here➡️ buff.ly/yLzNHzG

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc
Hurdles to providing equitable surgical care for ovarian cancer - VJOncology
Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, emphasizes the importance of accessibility as a major barrier in providing...
buff.ly
October 13, 2025 at 8:02 AM
vjoncology.bsky.social
🎥Aslı Doğa Munzur, BSc, discusses clonal hematopoiesis (CH) as a potential biomarker in #mCRPC

⭐Ongoing work aims to define CH’s role in predicting blood disorder risk & guiding patient selection:

➡️https://buff.ly/Y9FKoJW

@ascocancer.bsky.social #ASCO25 #UroOnc #UroSoMe #PCSM
Clonal hematopoiesis monitoring as a future biomarker in mCRPC - VJOncology
Aslı Doğa Munzur, BSc, Vancouver Prostate Centre, Vancouver, Canada, speaks on the potential of clonal hematopoiesis (CH) as a biomarker...
buff.ly
October 10, 2025 at 2:54 PM
vjoncology.bsky.social
🎥Fabrice André, MD, PhD, argues against continuing the same CDK4/6 inhibitor after progression in HR+/HER2– #BreastCancer

Watch here➡️https://buff.ly/6Uqux4A

@myesmo.bsky.social #ESMOBreast25 #BCSM
Post-progression CDK4/6 inhibitors in breast cancer: a failing strategy? - VJOncology
Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, shares his rationale against the continuation of CDK4/6 inhibitors following disease progression...
buff.ly
October 9, 2025 at 10:59 PM
vjoncology.bsky.social
⭐Christina Fotopoulou, MD, PhD, reports TRUST: primary debulking surgery improved PFS in advanced ovarian cancer, though OS was similar across arms:

🎥 buff.ly/DEDNtYW

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc
TRUST: optimal timing of surgical therapy in advanced ovarian cancer - VJOncology
Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the...
buff.ly
October 7, 2025 at 2:02 PM